Filing Details
- Accession Number:
- 0001104659-20-007260
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-27 19:01:46
- Reporting Period:
- 2020-01-23
- Accepted Time:
- 2020-01-27 19:01:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc. | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1493811 | Christian Weyer | C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001 | Evp, Research & Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-01-23 | 4,800 | $0.00 | 18,560 | No | 4 | A | Direct | |
Common Stock | Disposition | 2020-01-27 | 723 | $94.04 | 17,837 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Acquisiton | 2020-01-23 | 7,900 | $0.00 | 7,900 | $99.66 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
7,900 | 2030-01-23 | No | 4 | A | Direct |
Footnotes
- Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
- This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.